Day: October 20, 2020

29841-69-8, (1S,2S)-(-)-1,2-Diphenylethylenediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

0.592 g (2.79 mmol) of (S,S)-DPEN (MW: 212.3) was introduced into a 50-mL three-necked flask and subjected to argon-gas replacement. 25 mL of dehydrated methylene chloride and 0.41 mL (2.93 mmol) of triethylamine were added and cooled to 0 C. To this solution, a solution consisting of 0.515 g (2.79 mmol) of isohexyl sulfonyl chloride (MW: 184.68) and 25 mL of dehydrated methylene chloride was slowly added dropwise, and stirred at 0 C. for one night. This solution was washed twice with water, then the solvent in the organic layer was distilled away, and dried under reduced pressure to give 1.656 g of a crude product. The crude product was purified by silica-gel column chromatography (silica gel 60N, n-hexane:AcOEt=1:1, then AcOEt 100%) to give 0.306 g of (S,S)-(C2H5)2CHCH2SO2DPEN (30% yield). 1H NMR (400 MHz, CDCl3, rt, delta/ppm): 0.67 (q, J=7.3 Hz, 6H, (C3CH2)2CH), 1.10-1.38 (m, 4H, (CH3C2)2CH), 1.62-1.76 (m, 1H, (CH3CH2)2C), 2.22 (d, J=6.4 Hz, 2H, C2SO2), 4.29 (d, J=5.5 Hz, 1H, C6H5CNH2), 4.56 (d, J=5.5 Hz, 1H, C6H5CNHSO2), 7.15-7.45 (m, 10H, aromatic proton).

29841-69-8, 29841-69-8 (1S,2S)-(-)-1,2-Diphenylethylenediamine 6931238, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Kanto Kagaku Kabushiki Kaisha; US2010/261924; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.119-91-5,2,2′-Biquinoline,as a common compound, the synthetic route is as follows.

Example: Zetaeta(NuO3) 2 ¡¤ 6H20 (29.7 mg, 0.1 mmol), 2,2′-biquinoline (25.6 mg, 0.1 mmol), 2,2 -biphenyl diacid (24.0 mg, 0.1 mmol) and NaN3 (13.2 mg, 0.2 mmol), were added to a mixed solvent of 12 mL methanol and secondary deionized water (1:1 volume ratio), It was sealed in a 25 mL stainless steel container lined with tetrafluoroethylene, heated to 140 C for 3 days, and then slowly cooled to room temperature. After filtration, the filter cake was washed with diethyl ether and dried in air to obtain colorless massive crystals, the calculated yield based on Zn(N03)2¡¤6H20 was approximately 61%. This material was insoluble in water and other organic solvents.

119-91-5, As the paragraph descriping shows that 119-91-5 is playing an increasingly important role.

Reference£º
Patent; Anqing Teachers College; Xu Heng; Yan Da; Feng Xuejun; Chen Zhengxiang; Xiong Zhi; Huang Rongyi; (9 pag.)CN108017661; (2018); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.29841-69-8,(1S,2S)-(-)-1,2-Diphenylethylenediamine,as a common compound, the synthetic route is as follows.

To a solution of (S,S)-1,2-diphenylethane-1,2-diamine (424 mg,2 mmol) and triethylamine (280 muL, 2 mmol) in CH2Cl2 (10 mL), 4-(bromomethyl)phenylsulfonyl chloride 1 (525 mg, 1.96 mmol) in dichloromethane(10 mL) were added dropwise at 0 C. The reactionmixture was stirred at room temperature for 0.5 h. After removal ofsolvents under reduced pressure, the residue was purified by silica gelcolumn chromatography. The product 3 was obtained as white solid(0.45 g, 60%). 1H NMR (400 MHz, CDCl3) delta 7.46-7.31 (m, 2H),7.27-6.98 (m, 12H), 4.50 (s, 2H), 4.45 (d, J=5.1 Hz, 1H), 4.20 (d,J=5.2 Hz, 1H). 13C NMR (100 MHz, CDCl3) delta 141.5, 140.0, 136.9,129.0, 128.6, 128.3, 128.2, 127.7, 127.5, 127.5, 127.4, 63.0, 60.0,31.7. HRMS (ESI): m/z calculated for C21H21N2O2SBr [M+H]+:445.0580; found: 445.0583., 29841-69-8

29841-69-8 (1S,2S)-(-)-1,2-Diphenylethylenediamine 6931238, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Zheng, Dongsong; Liu, Rui; Wang, Yu; Cheng, Tanyu; Liu, Guohua; Molecular catalysis; vol. 455; (2018); p. 103 – 107;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2390-68-3,N-Decyl-N,N-dimethyldecan-1-aminium bromide,as a common compound, the synthetic route is as follows.,2390-68-3

Didecyldimethylammonium bromide (0.005 mol) was dissolved 100 mL of 95% ethanol by gentle stirring. Docusate sodium was dissolved in 50 mL of 95% ethanol by gentle stirring. The two solutions were combined and the reaction mixture was stirred for 1 hour at room temperature. A rotary evaporator removed the ethanol to give the ionic liquid and NaBr. The ionic liquid was dissolved in hexane and the NaBr was filtered off. A rotary evaporator removed the hexane to give a white solid obtained in a 78.00% yield. 1H and 13C NMR (DMSO) were obtained. Melting point (hot plate apparatus)=25-30 C.

The synthetic route of 2390-68-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Rogers, Robin D.; Daly, Daniel T.; Swatloski, Richard P.; Hough, Whitney L.; Davis, James Hilliard; Smiglak, Marcin; Pernak, Juliusz; Spear, Scott K.; US2007/93462; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4730-54-5, 1,4,7-Triazacyclononane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,4730-54-5

To a25 mL round bottom flask was added 157.5 mg(1.219 mmol)TACN (1,4,7-triazacyclononane), 3.4 equivalents of 2-bromoacetamide (565.7 mg, 4.100 mmol), and 12 mL ethanol. 3.5 mL triethylamine was added dropwise over several minutes until the solution turned cloudy and persisted, then the mixture was refluxed for 3 hours. After cooling, the mixture was decanted to remove most of the liquid, then 20 mL of warm80% ethanol/20 % water was added to yield a slightly opaque white solution resembling nonfat milk. The volume was slightly reduced under vacuum on a Schlenk line, then placed in the freezer for 3 days to recrystallize. After allowing white crystals to form, the solvent was removed by decanting and further dried under vacuum on the Schlenk line (90 % yield).ESI-MS: m/z = 301.3 (100 %), 302.3 (20 %) [M + H]+; 323.3 (25 %) [M + Na]+. 500 MHz?H NMR spectrum, D20 + DC1: ppm = 3.96 (s, 6H, amide CH2); 3.44 (s, 12H, ring CH2). 75MHz 13C NMR spectrum, D20: ppm = 173.64 (amide CO), 56.75 (amide CH2), 49.30 (ring CH2).

4730-54-5 1,4,7-Triazacyclononane 188318, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK UNIVERSITY AT BUFFALO; HEALTH RESEARCH, INC.; MORROW, Janet, R.; TSITOVICH, Pavel, B.; DORAZIO, Sarina, J.; OLATUNDE, Abiola, O.; SNYDER, Eric, M.; SPERNYAK, Joseph, A.; BURNS, Patrick; BOND, Christopher, J.; WO2015/38943; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

29841-69-8, (1S,2S)-(-)-1,2-Diphenylethylenediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Bis-aldehyde c (0.53 g,1.1 mmol) in dry THF (1.2 mL) was taken in a single-necked 50 mL round-bottom flask to which the solution of 1S,2S-(+)-1,2-diaminocyclohexane (0.14 g,1.2 mmol)/1S,2S-(-)-1,2-diphenylethane-1,2-diamine (0.27 g, 1.2 mmol) in dry THF (0.6 mL) was added slowly and the resultant solutions were stirred at room temperature. After completion of the reaction (2 h) checked on TLC, the solvent was removed completely under reduced pressure. The bright yellow solids were extracted with dichloromethane (50 mL), and the organic layer was washed with water (3 ¡Á 50 mL), brine (3 ¡Á 50 mL) and finally dried over anhydrous Na2SO4. After removal of dichloromethane under reduced pressure, the chiral dimeric macrocyclic ligands 3′ and 4′ were purified by silica gel chromatography (100-200 mesh) with a EtOAc-to-Hexane of 3:2.3′: Yield 96%. m.p. 76 C. 1H NMR (500 MHz, CDCl3): delta 1.38 (36H, s),1.67-1.93 (16H, m), 3.32 (4H, m), 3.55 (8H, t, J = 5), 3.61 (16H, t, J = 7), 4.37 (8H, s), 6.97 (4H, s), 7.20 (4H, s), 8.26 (4H, s), 13.86 (4H, br) ppm. 13C NMR (125 MHz, CDCl3): 25.0, 31.0, 34.7, 70.7, 72.2, 74.0, 74.8, 79.0, 119.8, 128.7, 131.2, 138.8, 161.6, 167.0 ppm; FT-IR (KBr): nu 3424, 2934, 2863, 2361, 1628, 1537, 1446, 1384, 1317, 1239, 1098, 940, 868, 785, 671, 563, 420 cm-1. (c = 0.052, CH2Cl2). Anal. Calcd. for C72H104N4O12 C, 71.02; H, 8.61; N, 4.60. Found C, 71.05; H, 8.63; N, 4.62. MALDI-TOF: m/z Calcd. for [C72H104N4O12] 1217.62, Found 1218.19 [M+H].4′: Yield 93%. m.p. 95 C. 1H NMR (200 MHz, CDCl3): delta 1.40 (36H, s), 3.53-3.63 (24H, m), 4.37 (8H, s), 4.71 (4H, s), 6.97 (4H, s), 7.19-7.29 (24H, m), 8.32 (4H, s), 13.78 (4H, br) ppm. 13C NMR (50 MHz, CDCl3): 29.3, 34.8, 69.1, 70.6, 73.1, 80.0, 118.1, 127.6, 128.1, 128.3, 129.8, 137.3, 139.5, 159.9, 166.7 ppm. FT-IR (KBr): nu 3452, 2952, 2865, 2361, 1626, 1446, 1386, 1357, 1320, 1266, 1208, 1100, 1035, 936, 871, 801, 775, 573 cm-1. (c = 0.108, CHCl3). Anal. Calcd. for C88H108N4O12 C, 74.76; H, 7.70; N, 3.96. Found C, 74.75; H, 7.73; N, 3.98. MALDI-TOF: m/z Calcd. for [C88H108N4O12] 1413.82, Found 1414.19 [M+H].

29841-69-8, The synthetic route of 29841-69-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Kureshy, Rukhsana I.; Roy, Tamal; Khan, Noor-Ul H.; Abdi, Sayed H.R.; Sadhukhan, Arghya; Bajaj, Hari C.; Journal of Catalysis; vol. 286; (2012); p. 41 – 50;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

78902-09-7,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.78902-09-7,2-(2,2-Diethoxyethyl)isoindoline-1,3-dione,as a common compound, the synthetic route is as follows.

2-{2-ethoxy-2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]ethyl}-1H-isoindole-1,3(2H)-dione (Compound 42) To 50 ml dichloromethane solution of 2-(2,2-diethoxyethyl)-1H-isoindole-1,3(2H)-dione (6.8 g, 25.8 mmol) under an ice bath was added 2,6-lutidine (9.89 mL, 85 mmol) and TMSOTf (10.3 mL, 56.8 mmol). The reaction stirred under the ice bath for one hour. After which, (9Z,12Z)-octadeca-9,12-dien-1-ol (24.3 mL, 77 mmol) was added in and the reaction was stirred from 0 C. to 20 C. for 16 hours. The reaction was diluted with 200 mL dichloromethane and washed by 100 mL of NaHCO3 solution, water, brine. The organic was dried over Na2SO4, filtrated and purified by silica gel chromatography (0% ethyl acetate/hexane?18% ethyl acetate/hexane) to give title compound (12.1 g). MS 506.5 (M+Na).

The synthetic route of 78902-09-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SIRNA THERAPEUTICS, INC.; Colletti, Steven L.; Deng, Zhengwu James; Stanton, Matthew G.; Wang, Weimin; Hills, Ivory; (47 pag.)US9670487; (2017); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5,62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of N((5-(5-(difluoromethyl)- 1,3 ,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), D-(-)-Prolinamide (0.058 g, 0.5 10 mmol) and Diisopropylethylamine (0.176 mL, 1.019 mmol) in dichioromethane (5 mL) was stirred at the room temperature for 24 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Si02, 12 g cartridge; methanol / dichloromethane = 5 % to 10 %) to give(R)- 1 -(2-(N-((5-(5-(difluoromethyl)- 1,3 ,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phen ylsulfamoyl)ethyl)pyrrolidine-2-carboxamide as white solid (0.045 g, 34.9 %).?H NMR(400 MHz, CD3OD): oe 9.17 (dd, 1 H, J= 2.2, 0.8 Hz), 8.43 (dd, 1 H, J=8.3, 2.3 Hz), 7.76 (dd, 1 H, J = 8.2, 0.8 Hz), 7.55 – 7.44 (m, 2 H), 7.46 – 7.35 (m, 1 H),7.40 – 7.19 (m, 3 H), 5.17 (s, 2 H), 3.63 – 3.46 (m, 2 H), 3.32 – 2.76 (m, 3 H), 2.65 (q, 1H, J= 7.3 Hz), 2.45 -2.28 (m, 1 H), 2.30-2.12 (m, 1 H), 1.92- 1.71 (m, 3 H); LRMS(ES) mlz 507.3 (M¡Â+1).

The synthetic route of 62937-45-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; CHONG KUN DANG PHARMACEUTICAL CORP.; LEE, Jaekwang; HAN, Younghue; KIM, Yuntae; CHOI, Daekyu; MIN, Jaeki; BAE, Miseon; YANG, Hyunmo; KIM, Dohoon; (644 pag.)WO2017/18803; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

99970-84-0, [2,2′-Bipyridine]-4,4′-dicarbaldehyde is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

99970-84-0, Dry potassium carbonate (1.7 g, 12.3 mmol) and 2.1 gtriethylphosphonoacetate were suspended in 10 cm3 of anhydrousTHF and stirred at room temperature for 15 min beforethe suspension was refluxed for 20 min. After cooling thesuspension to room temperature it was transferred into amicrowave vessel and 1.0 g (4.7 mmol) of (7) in 2 cm3 anhydrousTHF were added. The vessel was sealed and heated to110 C within 10 min using a maximum power of 1000MW.The reaction temperature then was maintained for 2 h afterwhich the vessel was allowed to cool down to room temperature.After cooling, 20 cm3 of a 10% potassium carbonatesolution was added. The mixture was extracted three timeswith ethyl acetate. The organic phase was dried over sodiumsulfate and the solvent was evaporated under reduced pressure.The remaining triethylphosphonoacetate was removedby distillation in vacuo. The crude product was purified bycolumn chromatography on silica gel using a diethyl ether:light petroleum (40-60) 1 : 1 mixture as the eluent. After thesolvent mixture was evaporated a white solid was obtainedwhich was recrystallized from ethanol/water by first dissolvingthe crude product in ethanol and then adding wateruntil the solution misted. For complete crystallization thesolution was placed in the refrigerator. Yield: 40% (0.66 g,1.88 mmol).IR (298 K) [cm-1]: 2980w, 2936vw, 1726vs, 1697vs,1584m, 1545w, 1458m, 1443m, 1377s, 1294s, 1263s, 1217vs,1063vs, 1011s, 991m, 930w, 880w, 860w, 843m, 791s, 770w,746m; MS (EI) m/z (%): 352 (10) [M+]; 323 (5) [M+-C2H5]; 308 (70) [M+-C2H5 – CH3]; 280 (100) [M+-C4H9O];261 (20) [M+-C4H11O2]; 233 (25) [M+-C6H15O2]; 208 (70)[M+-C8H18O2]; 1HNMR(CDCl3):delta ppm 1.36 (t, J = 7.07Hz, 6 H) 4.30 (q, J = 7.16 Hz, 4 H) 6.73 (s, 1 H) 6.77 (s, 1H) 7.41 (dd, J = 5.05, 1.77 Hz, 2 H) 7.73 (s, 1 H) 7.69 (s, 1H) 8.55-8.58 (m, 2 H) 8.73 (d, J = 5.05 Hz, 2 H); 13C-NMR(CDCl3):delta [ppm] = 14.2, 61.0, 119.3, 122.2, 123.1, 141.8,142.8, 150.0, 156.4, 166.1; M.p.: 139 C; elemental analysis:calc. (%) for C20H20N2O4: C 68.17, H 5.72, N 7.95; found:C 67.30, H 5.66, N 8.03.

As the paragraph descriping shows that 99970-84-0 is playing an increasingly important role.

Reference£º
Article; Heintz, Katharina; Goerls, Helmar; Imhof, Wolfgang; Journal of Chemical Sciences; vol. 130; 6; (2018);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787-70-2,[1,1′-Biphenyl]-4,4′-dicarboxylic acid,as a common compound, the synthetic route is as follows.,787-70-2

In a typical preparation, a solid mixture of H2BPDC (H2BPDC = 4,4′-biphenyldicarboxylic acid; 0.1039 g, 0.4 mmol), BPY (BPY = 4,4′-bipyridine; 0.033 g, 0.2 mmol), and Cu(NO3)2.3H2O (0.105 g, 0.4 mmol) was dissolved in a mixture of DMF (DMF = N,N’-dimethylformamide; 30 mL), pyridine (0.3 mL), and methanol (3 mL). The resulting solution was stirred at 70 C for 5 min, and then distributed to four 20 mL vials. The vials were then heated at 120 C in an isothermal oven for 24 h. After cooling the vials to room temperature, the solid product was removed by decanting with mother liquor and washed in DMF (3 * 10 mL) for 3 days. Solvent exchange was carried out with methanol (3 * 10 mL) at room temperature for 3 days. The material was then evacuated under vacuum at 140 C for 6 h, yielding 0.103 g of Cu2(BPDC)2(BPY) in the form of blue crystals (67.5% based on copper nitrate).

The synthetic route of 787-70-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Le, Hanh T.N.; Nguyen, Tung T.; Vu, Phuong H.L.; Truong, Thanh; Phan, Nam T.S.; Journal of Molecular Catalysis A: Chemical; vol. 391; 1; (2014); p. 74 – 82;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI